Get started

PHARMA

BIOSEARCH: Potential H&S despite good fundamentalsOn July 10, after issuing a warning that the firm would expect higher than usual profits, BIOS jumped >20% that friday. Then, once its quarterly earnings were released, it was clear the company had not tricked us: + 25.8% REVENUES OF 14.3 MILLION IN THE FIRST SEMESTER, +44.2% to 5.5 million euros in Plant extracts business line, probiotics business registered a growth of 47.4%, standing at 3.2 million euros, driven mainly by the Women’s Health segment. Net profit was up +501,7% in the first semester of 2020. EBITDA of €1,96 million (+92,8% Semester over Semester). However, technical analysis suggests to short the company until 1.04 or even 0.95 level (and some other analysts from FX Street say 0.87). As it is usual in summer, the company is experiencing low volume levels so if volume starts increasing, BIOS' share price may go up easily as Reig Jofre or ROVI did. So, long-term trend is bullish up until 2018 maximums of 1.95-2€. August is bearish. relatively high PER: (57*1.13)/1.04 = 62 Not higher than RJFE's PER = 77 ROVI's PER = 95 And lower than: FAES FARMA PER = 21.53 (very undervalued in my opinion) PHARMA MAR PER = 14 (unstable company, needs more history to determine its viability. it could certainly be a good investment due to its low PER, but remember first semester 2019 it experienced losses instead of profits) These PERs here were calculated based on net profit from first semester 2020 only.
BShort
by alexinve
Long biased w/ recent settlement with Apotex and tight range.21-May-20 16:10 ET AMRN Amarin announces trial to evaluate effects of VASCEPA on patients with COVID-19 (7.28 -0.18) Amarin today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA) on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial primary endpoint is the effect of VASCEPA versus usual care on high-sensitivity C-reactive protein levels from baseline to 14 days in adults with a COVID-19-positive diagnosis. The clinical study design also includes other endpoints that assess rates and severity of COVID-19 infection in this high-risk group. The company states, "Based on our current understanding of the biological effects of a COVID-19 infection, including that patients at high risk of cardiovascular disease are at higher risk of mortality and severe effects from a COVID-19 infection, and based on data related to the mechanism of action and effects of VASCEPA in lowering cardiovascular risk in certain high-risk patients, it is believed that VASCEPA could play a beneficial clinical role in helping patients infected by the virus." 14-May-20 14:52 ET AMRN Amarin announces VASCEPA data from prespecified and post hoc analyses of REDUCE-IT study (7.64 +0.22) Amarin today announced that data from the REDUCE-IT study presented at the Society for Cardiovascular Angiography & Interventions 2020 Scientific Sessions,showed that administration of 4 g/day of VASCEPA (icosapent ethyl) resulted in a significant 34% reduction in first coronary revascularizations versus placebo (p<0.0001). Similar reductions of 36% were observed in total, or first and subsequent, revascularizations (p<0.0001). The analyses from the REDUCE-IT study included several types of coronary revascularization events in statin-treated patients with persistent elevated triglycerides (135-499 mg/dL), who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including urgent, emergent, and elective revascularizations, which were reduced by 34% (p<0.0001), 38% (p=0.02), and 32% (p<0.0001), respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention (PCI) by 32% (p<0.0001) and coronary artery bypass grafting (CABG) by 39% relative to placebo (p=0.0005).
NASDAQ:AMRNLong
by SwingingForward
$MNK One last HoorahTwo reasons for posting this chart. 1) MNK is a long standing established generic and specialty manufacturer with products that have real usage. This is NOT a one hit wonder biotech. It would be bought out before full bankruptcy. 2) More importantly, when was the last time you've seen a CLEAR bullish divergence on a MONTHLY chart? This will be a bag I hold probably until the end of 2020, but I expect it's first leg breaking out of its downtrend within the next 6 weeks. A Monthly bullish divergence MUST not be ignored. If you have money you are not actively trading with, THIS is where you put it. As you can see the accumulation volume over the last 6 months is there as well. Weekly has bullish divergences as well. On a shorter time frame, the daily is flagging. Breakout point 3.20 with target of 5 dollars.
MLong
by Matewan3291